| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.89(B) |
| Last
Volume: |
639,983 |
Avg
Vol: |
1,080,540 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,112 |
8,699 |
11,368 |
11,368 |
| Total Sell Value |
$97,579 |
$136,292 |
$185,375 |
$185,375 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
2 |
3 |
3 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hannah Alison L. |
Director |
– • – |
2016-04-20 |
4 |
A |
$7.15 |
$15,373 |
D/D |
2,150 |
13,710 |
|
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2016-04-20 |
4 |
A |
$7.15 |
$15,373 |
D/D |
2,150 |
16,710 |
|
- |
|
| Johnson Kevin C |
Director |
– • – |
2016-04-20 |
4 |
A |
$7.15 |
$15,373 |
D/D |
2,150 |
119,904 |
|
- |
|
| Cardoza George |
Chief Financial Officer |
• – – |
2016-03-11 |
4 |
S |
$6.83 |
$218,560 |
D/D |
(32,000) |
189,089 |
|
- |
|
| Cardoza George |
Chief Financial Officer |
• – – |
2016-03-11 |
4 |
OE |
$1.46 |
$146,000 |
D/D |
100,000 |
221,089 |
|
- |
|
| Brodie Steven G. |
Chief Scientific Officer |
• – – |
2016-03-10 |
4 |
OE |
$1.48 |
$74,000 |
D/D |
50,000 |
55,953 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• – – |
2016-03-09 |
4 |
S |
$6.93 |
$1,108,800 |
D/D |
(160,000) |
1,675,000 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• – – |
2016-03-08 |
4 |
S |
$7.19 |
$2,085,100 |
D/D |
(290,000) |
1,835,000 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• – – |
2016-03-08 |
4 |
OE |
$0.80 |
$800,000 |
D/D |
1,000,000 |
2,125,000 |
|
- |
|
| Johnson Kevin C |
Director |
– • – |
2016-03-04 |
4 |
B |
$6.84 |
$49,296 |
D/D |
7,207 |
117,754 |
2.39 |
- |
|
| Johnson Kevin C |
Director |
– • – |
2016-03-03 |
4 |
B |
$6.75 |
$99,900 |
D/D |
14,800 |
110,547 |
2.39 |
- |
|
| Hannah Alison L. |
Director |
– • – |
2016-03-03 |
4 |
B |
$6.90 |
$69,000 |
D/D |
10,000 |
11,560 |
2.39 |
- |
|
| Ge Medical Systems Information Technologies, Inc. |
10% Owner |
– – • |
2015-12-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,000,000 |
|
- |
|
| Horel Robert H. |
Vice President GM PathLogic |
• – – |
2015-12-29 |
4 |
OE |
$1.45 |
$80,266 |
D/D |
51,218 |
51,218 |
|
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2015-12-21 |
4 |
B |
$8.21 |
$77,995 |
D/D |
9,500 |
14,560 |
2.39 |
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2015-12-07 |
4 |
B |
$7.72 |
$27,020 |
D/D |
3,500 |
5,060 |
2.39 |
- |
|
| Shovlin Robert J. |
Chief Operating Officer |
• – – |
2015-12-03 |
4 |
B |
$7.75 |
$50,763 |
D/D |
6,550 |
6,550 |
2.74 |
- |
|
| Aspen Select Healthcare Lp |
Executive VP of Finance |
– – • |
2015-11-27 |
4 |
GD |
$8.05 |
$201,250 |
D/D |
25,000 |
286,251 |
|
- |
|
| Aspen Select Healthcare Lp |
Executive VP of Finance |
– – • |
2015-11-27 |
4 |
S |
$8.06 |
$282,065 |
I/I |
(35,000) |
3,327,745 |
|
- |
|
| Aspen Select Healthcare Lp |
Executive VP of Finance |
– – • |
2015-11-25 |
4 |
S |
$8.10 |
$2,833,250 |
I/I |
(350,000) |
3,362,745 |
|
- |
|
| Crowther Bruce K |
Director |
– • – |
2015-11-02 |
4 |
B |
$7.81 |
$49,978 |
I/I |
6,400 |
9,980 |
2.1 |
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2015-06-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,560 |
|
- |
|
| Hannah Alison L. |
Director |
– • – |
2015-06-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,560 |
|
- |
|
| Brodie Steven G. |
Chief Scientific OfficerOffice |
• – – |
2015-04-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,482 |
|
- |
|
| Balliet Jennifer |
Vice President Human Resources |
• – – |
2015-04-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
465 |
|
- |
|
544 Records found
|
|
Page 17 of 22 |
|
|
0.19 (1.27%) 
